423 related articles for article (PubMed ID: 24880341)
1. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
[TBL] [Abstract][Full Text] [Related]
2. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
[TBL] [Abstract][Full Text] [Related]
3. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
4. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
[TBL] [Abstract][Full Text] [Related]
5. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
7. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of diffuse intrinsic brainstem gliomas in adults.
Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M
J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757
[TBL] [Abstract][Full Text] [Related]
9. Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases.
El Ayoubi R; Boisselier B; Rousseau A
J Neurooncol; 2017 Sep; 134(2):465-467. PubMed ID: 28589424
[No Abstract] [Full Text] [Related]
10. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
11. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka P; Reitman ZJ; Lu S; Buchan G; Gionet G; Dubois F; Carvalho DM; Shih J; Zhang S; Greenwald NF; Zack T; Shapira O; Pelton K; Hartley R; Bear H; Georgis Y; Jarmale S; Melanson R; Bonanno K; Schoolcraft K; Miller PG; Condurat AL; Gonzalez EM; Qian K; Morin E; Langhnoja J; Lupien LE; Rendo V; Digiacomo J; Wang D; Zhou K; Kumbhani R; Guerra Garcia ME; Sinai CE; Becker S; Schneider R; Vogelzang J; Krug K; Goodale A; Abid T; Kalani Z; Piccioni F; Beroukhim R; Persky NS; Root DE; Carcaboso AM; Ebert BL; Fuller C; Babur O; Kieran MW; Jones C; Keshishian H; Ligon KL; Carr SA; Phoenix TN; Bandopadhayay P
Nat Commun; 2022 Feb; 13(1):604. PubMed ID: 35105861
[TBL] [Abstract][Full Text] [Related]
12. Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
Reitman ZJ
Pharmacogenomics; 2014 Sep; 15(13):1639-41. PubMed ID: 25410889
[No Abstract] [Full Text] [Related]
13. H3F3A K27M mutations in thalamic gliomas from young adult patients.
Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Liang C; Guo E; Lu S; Wang S; Kang C; Chang L; Liu L; Zhang G; Wu Z; Zhao Z; Ma S; Wang L; Jiao BH
Brain Res; 2012 Mar; 1444():65-75. PubMed ID: 22325093
[TBL] [Abstract][Full Text] [Related]
15. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
16. Distinct molecular profile of diffuse cerebellar gliomas.
Nomura M; Mukasa A; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Suzuki T; Otani R; Kobayashi K; Maruyama T; Tanaka S; Takayanagi S; Nejo T; Takahashi S; Ichimura K; Nakamura T; Muragaki Y; Narita Y; Nagane M; Ueki K; Nishikawa R; Shibahara J; Aburatani H; Saito N
Acta Neuropathol; 2017 Dec; 134(6):941-956. PubMed ID: 28852847
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
[TBL] [Abstract][Full Text] [Related]
19. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
